Corrigendum: Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma (International Journal of Oncology (2013) 42 (690-698) DOI: 10.3892/ijo.2012.1741);Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 690-698

  Yang, Wei ^a   Wang, Xiaoyuan ^a   Zheng, Wei ^a   Li, Kedong ^a   Liu, Haofeng ^a   Sun, Yueming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; DNA methylation; Histone deacetylation; MiR 21; RAS; Tumor suppressor gene tropomyosin 1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 AZA 2' DEOXYCYTIDINE; ALPHA TROPOMYOSIN; HISTONE; LENTIVIRUS VECTOR; MANUMYCIN; MICRORNA 21; TETRAZOLIUM; TRICHOSTATIN A;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RAS SIGNALING PATHWAY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING;

EID: 84873629700     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3749     Document Type: Erratum

References (41)

1. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1304, 2005.
2. Hong K and Geschwind JF: Locoregional: intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol 37: 110-117, 2010.
3. Ramage JK, Donaghy A, Farrant JM, Iorns R and Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108: 865-869, 1995.
4. Schevzov G, Whittaker SP, Fath T, Lin JJ and Gunning PW: Tropomyosin isoforms and reagents. Bioarchitecture 1: 135-164, 2011.
5. Lin JJ, Warren KS, Wamboldt DD, Wang T and Lin JL: Tropomyosin isoforms in non-muscle cells. Int Rev Cytol 170: 1-38, 1997.
6. Bharadwaj S and Prasad L: Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. Cancer Lett 183: 205-213, 2002.
7. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T and Prasad GL: Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 22: 6194-6203, 2003.
8. Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB and Helfman DM: Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer 110: 368-373, 2004.
9. Yager ML, Hughes JA, Lovicu FJ, Gunning PW, Weinberger RP and O'Neill GM: Functional analysis of the actin binding protein, tropomyosin 1, in neuroblastoma. Br J Cancer 89: 860-863, 2003.
10. Choi C, Kim D, Kim S, Jeong S, Song E and Helfman DM: From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. J Struct Biol 177: 63-69, 2012.
11. Mahadev K, Raval G, Bharadwaj S, et al: Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res 279: 40-51, 2002.
12. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H and Helfman DM: A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell 15: 4682-4694, 2004.
13. Xu RF, Sun JP, Zhang SR, et al: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 65: 22-26, 2011.
14. O'Dell MR, Huang JL, Whitney-Miller CL, et al: Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 15: 1557-1567, 2012.
15. Imai M and Takahashi N: Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma. Bioorg Med Chem 20: 2520-2526, 2012.
16. Jinawath A, Akiyama Y, Sripa B and Yuasa Y: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol 133: 271-278, 2007.
17. Hara M, Akasaka K, Akinaga S, et al: Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90: 2281-2285, 1993.
18. Nagase T, Kawata S, Tamura S, et al: Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.Int J Cancer 65: 620-626, 1996.
19. Kainuma O, Asano T, Hasegawa M, Kenmochi T, Nakagohri T, Tokoro Y and Isono K: Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 15: 379-383, 1997.
20. Ito T, Kawata S, Tamura S, et al: Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res 87: 113-116, 1996.
21. Shields JM, Mehta H, Pruitt K and Der CJ: Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin. Mol Cell Biol 22: 2304-2317, 2002.
22. Varga AE, Stourman NV, Zheng Q, et al: Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene 24: 5043-5052, 2005.
23. Liu S, Ren S, Howell P, Fodstad O and Riker AI: Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21: 545-558, 2008.
24. Kawahigashi Y, Mishima T, Mizuguchi Y, et al: MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nihon Med Sch 76: 188-197, 2009.
25. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007.
26. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008.
27. Li J, Huang H, Sun L, et al: MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998-4008, 2009.
28. Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285, 2009.
29. Dong CG, Wu WK, Feng SY, Wang XJ, Shao JF and Qiao J: Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. Int J Oncol 41: 1005-1012, 2012.
30. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW and Baba HA: AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13: 6470-6477, 2007.
31. Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13: 1561-1568, 2007.
32. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 9: 3, 2009.
33. Menakongka A and Suthiphongchai T: Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol 16: 713-722, 2010.
34. Wu T, Leng J, Han C and Demetris AJ: The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3: 299-307, 2004.
35. Matsumoto K, Nagahara T, Okano J and Murawaki Y: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 20: 863-872, 2008.
36. Liu XF, Jiang H, Zhang CS, Yu SP, Wang ZQ and Su HL: Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells. J Int Med Res 40: 67-75, 2012.
37. Xu LN, Wang X and Zou SQ: Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World J Gastroenterol 14: 2578-2581, 2008.
38. Yin P, Zhao C, Li Z, et al: Sp1 is involved in regulation of cystathionine gamma-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. Cell Signal 24: 1229-1240, 2012.
39. Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK and Lin JY: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32: 138-145, 2011.
40. Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell line. Gastroenterology 130: 2113-2129, 2006.
41. Wehbe H, Henson R, Meng F, Mize-Berge J and Patel T: Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66: 10517-10524, 2006.